Chemistry Central Journal Poster presentation Identification of Plk1 type II inhibitors by structure-based virtual

Abstract

© 2009 Keppner et al; licensee BioMed Central Ltd. Protein kinases are targets for drug development [1]. Dysregulation of kinase activity leads to various diseases [2], e.g. cancer, inflammation, diabetes [1]. Human polo-like kinase 1 (Plk1), a serine/threonine kinase, is a cancer-relevant gene and a potential drug target which attracts increasing attention in the field of cancer therapy. Plk1 is a key player in mitosis and modulates entry into mitosis and the spindle checkpoint at the meta-/anaphase transition. Plk1 overexpression is observed in various human tumors, and it is a negative prognostic factor for cancer patients [3]. The same catalytical mechanism and the same co-substrate (ATP) lead to the problem of inhibitor selectivity. A strategy to solve this problem is represented by targetin